Ozempic went viral in late 2022 as demand outran supply

In late 2022, Ozempic became a mainstream cultural reference. TikTok videos, celebrity speculation and coverage of off-label use for cosmetic weight loss pushed the drug's name well beyond the patients who had been prescribed it for diabetes ^[1]. The attention fueled demand that the supply chain could not meet ^[1].

Ozempic is one brand of semaglutide, which is prescription-only in the United States ^[1]. The same molecule is sold as Rybelsus, an oral tablet, and as Wegovy ^[1]. Semaglutide is described as an anti-diabetic and anti-obesity medication, meaning it is used both for diabetes and for weight management ^[1]. Ozempic is given as an injection under the skin; Rybelsus is taken by mouth ^[1].

The version of the trend that spread in late 2022 was off-label use: people seeking cosmetic weight loss from a medicine prescribed for a diagnosed condition. Off-label prescribing is a routine part of medical practice, but it is not the same thing as a drug being approved for that purpose. How much of the late-2022 demand came from off-label use rather than ordinary prescriptions has not been reported.

What is documented about the medicine itself is more concrete. The injected form is 89 percent bioavailable; the oral form is 1 to 2 percent bioavailable ^[1]. Its elimination half-life is about 7 days, and its duration of action is listed at 63.6 hours ^[1]. It is cleared through urine and feces ^[1]. In the US it is available only by prescription ^[1].

How large the demand surge was, how many prescriptions were written for cosmetic reasons, and how deep the resulting shortages ran has not been disclosed. Figures on those points are not yet available.

Why it matters for patients

Ozempic, Rybelsus and Wegovy all contain the same active ingredient, semaglutide, so attention aimed at one brand lands on the molecule as a whole ^[1]. A person who takes Ozempic for diabetes or Wegovy for obesity is using the same underlying drug as the people driving a viral trend, and when supply tightens, the wait is shared ^[1].

Because the drug is prescription-only in the US, a wave of social-media interest does not create a legal route to it ^[1]. It also does not change who a clinician is willing to prescribe it for. The gap between what a trend suggests and what a prescription requires is where much of the confusion for patients sits.

One practical detail holds regardless of the news cycle: the elimination half-life is about 7 days, and the duration of action is listed at 63.6 hours ^[1]. That means the medicine is not cleared from the body quickly after the last dose.

Finally, the attention changed the public conversation more than it changed the label. Ozempic remained a prescription medicine, and semaglutide remained the molecule sold under the Ozempic, Rybelsus and Wegovy brand names ^[1]. Off-label cosmetic use sat outside that framework, and the late-2022 coverage did not change the regulatory status of the drug in the United States ^[1].